Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Nancy Alvandi"'
Publikováno v:
Experimental Dermatology. 28:190-197
Acne remains as the most common skin disease in the United States even despite multiple approved topical and systemic medications available. These treatments available over the counter and by prescription can be classified based on comedolytic, antib
Autor:
Brian S. Biesman, Lei Luo, Michael H. Gold, Nancy Alvandi, Gurpreet Ahluwalia, Mark Lebwohl, Deanne Mraz Robinson, David R. Berk
Publikováno v:
Journal of the American Academy of Dermatology. 79:e57-e59
Autor:
Roy G. Geronemus, David J. Goldberg, Zane Bai, Nancy Alvandi, Jeffrey S. Dover, Stuart D. Shanler, Emil Tanghetti
Publikováno v:
Lasers in Surgery and Medicine
Background and objectives The objectives of this study were to evaluate the safety, tolerability, and efficacy of oxymetazoline hydrochloride cream, 1% (oxymetazoline) when used as an adjunctive treatment with energy-based therapy for patients with m
Publikováno v:
Antimicrobial Agents and Chemotherapy
Sarecycline is the first narrow-spectrum tetracycline-class antibiotic being developed for acne treatment. In addition to exhibiting activity against important skin/soft tissue pathogens, sarecycline exhibits targeted antibacterial activity against c
Autor:
Linda, Stein-Gold, Leon, Kircik, Zoe Diana, Draelos, Philip, Werschler, Janet, DuBois, Edward, Lain, Leslie, Baumann, David, Goldberg, Joely, Kaufman, Emil, Tanghetti, Gurpreet, Ahluwalia, Nancy, Alvandi, Emily, Weng, David, Berk
Publikováno v:
Journal of drugs in dermatology : JDD. 17(11)
Background: Rosacea is a chronic dermatologic condition with limited treatment options. Methods: Data were pooled from two identically designed phase 3 trials. Patients with moderate to severe persistent erythema of rosacea were randomized to receive
Publikováno v:
Journal of drugs in dermatology : JDD. 17(11)
Introduction: Acne vulgaris is more common in females than males and is challenging to treat. A post hoc analysis of 2 clinical trials evaluated the effect of dapsone gel, 7.5% based on sex and baseline acne lesion count. Methods: Two identically des
Autor:
J.Q. Del Rosso, Lawrence F. Eichenfield, Nancy Alvandi, Jerry Tan, Julie C Harper, Leon H Kircik, Hilary Baldwin, Guy F. Webster, Alexandre Kaoukhov, Adelaide A. Hebert, Linda Stein-Gold
Publikováno v:
The British journal of dermatology. 180(5)
Author(s): Eichenfield, LF; Del Rosso, JQ; Tan, JKL; Hebert, AA; Webster, GF; Harper, J; Baldwin, HE; Kircik, LH; Stein-Gold, L; Kaoukhov, A; Alvandi, N | Abstract: BackgroundOnce-daily topical oxymetazoline cream 1·0% significantly reduced persiste
Autor:
Emil A, Tanghetti, Jeffrey S, Dover, David J, Goldberg, Sunil S, Dhawan, Lei, Luo, David R, Berk, Gurpreet, Ahluwalia, Nancy, Alvandi
Publikováno v:
Journal of drugs in dermatology : JDD. 17(6)
Persistent facial erythema is a clinically challenging feature of rosacea.To evaluate persistent erythema reduction on the first day of treatment from pooled data from two pivotal trials of topical oxymetazoline cream 1.0% (oxymetazoline) in persiste
Publikováno v:
Journal of drugs in dermatology : JDD. 17(6)
Dapsone gel, 7.5% is a topical medication approved for acne in patients aged 12 years and older. Clinical trials have demonstrated the safety and efficacy of once-daily dapsone gel, 7.5% in patients with moderate acne.The objective of this report is
Autor:
Susan C, Taylor, Fran E, Cook-Bolden, Amy, McMichael, Jeanine B, Downie, David A, Rodriguez, Andrew F, Alexis, Valerie D, Callender, Nancy, Alvandi
Publikováno v:
Journal of drugs in dermatology : JDD. 17(2)
Acne vulgaris (acne) is prevalent in individuals with skin of color, often with more frequent sequelae than in patients with lighter skin color. It is important to determine if there are also differences in response to medications.This study evaluate